A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer
暂无分享,去创建一个
Sudhir Srivastava | David F. Ransohoff | Martin W. McIntosh | Robert C. Bast | Ruth M. Pfeiffer | Gil Mor | Paul F. Pinsky | Christos Patriotis | Nicole Urban | Anna E. Lokshin | Patrick M. Sluss | Karen H. Lu | R. Bast | E. Fung | P. Hartge | D. Ransohoff | C. Berg | S. Buys | S. Skates | Zhen Zhang | D. Ward | P. Pinsky | L. Moore | R. Pfeiffer | D. Cramer | N. Urban | G. Mor | A. Vitonis | P. Sluss | M. McIntosh | S. Srivastava | K. Lu | A. Lokshin | Claire S Zhu | N. Scholler | A. Lomakin | Patricia Hartge | Nathalie Scholler | Zhen Zhang | Aleksey Lomakin | Saundra S. Buys | Daniel W. Cramer | Steven J. Skates | Adele M. Marrangoni | Christine D. Berg | J. Symanowski | Allison Vitonis | Claire S. Zhu | Lee E. Moore | David C. Ward | James T. Symanowski | Eric T. Fung | A. Marrangoni | C. Patriotis | K. Lu | K. Lu | C. Berg
[1] William L. Bigbee,et al. Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[2] John P A Ioannidis,et al. Translation of highly promising basic science research into clinical applications. , 2003, The American journal of medicine.
[3] J. Gohagan,et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.
[4] Gary Goodman,et al. Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study , 2010, Journal of the National Cancer Institute.
[5] Jeffrey S. Morris,et al. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..
[6] Hongyu Zhao,et al. Serum protein markers for early detection of ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] Steven J Skates,et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.
[8] E. Diamandis. Proteomic patterns to identify ovarian cancer: 3 years on , 2004, Expert review of molecular diagnostics.
[9] David Chia,et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. , 2005, American journal of obstetrics and gynecology.
[10] Holly Janes,et al. Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.
[11] R. Bast,et al. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.
[12] D. Ransohoff. Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.
[13] N V Belinskaia,et al. [Early detection of ovarian cancer]. , 1978, Voprosy onkologii.
[14] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[15] Sudhir Srivastava,et al. Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens , 2011, Cancer Prevention Research.
[16] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[17] G. Anderson,et al. Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers , 2007, PloS one.
[18] L. Liotta,et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. , 2008, Clinical chemistry.
[19] Steven J Skates,et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[21] B. H. Patterson,et al. Evaluating markers for the early detection of cancer: overview of study designs and methods , 2006, Clinical trials.
[22] P. Brown,et al. Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian Cancer , 2008, PloS one.
[23] D. Ransohoff,et al. Sources of bias in specimens for research about molecular markers for cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Gohagan,et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. , 2000, Controlled clinical trials.
[25] D. Ward,et al. Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.
[26] J. Potter. Epidemiology informing clinical practice: from bills of mortality to population laboratories , 2005, Nature Clinical Practice Oncology.
[27] E. Fung,et al. Evaluation of Apolipoprotein A1 and Posttranslationally Modified Forms of Transthyretin as Biomarkers for Ovarian Cancer Detection in an Independent Study Population , 2006, Cancer Epidemiology Biomarkers & Prevention.
[28] P C Prorok,et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.
[29] Daniel W Chan,et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. , 2007, Gynecologic oncology.
[30] R. Bast,et al. Validation of Biomarker Panels for Ovarian Cancer A Framework for Evaluating Biomarkers for Early Detection : Updated , 2011 .